Autoantibodies are known to be involved in systemic lupus erythematosus and other autoimmune diseases. More recently,
severe COVID-19 patients were also shown to harbor auto-antibodies against type I interferons. It is important to be able to
quantitate the extent of the action of these autoantibodies in neutralizating or stabilizating inflammatory molecules. The difficulty arises when circulating levels of these molecules are so low that standard techniques are not suited for this evaluation. The digital counting of single molecules by Simoa bead technology allows quantitation of baseline levels of IFNα and cytokines, enabling researchers to evaluate the magnitude of action of autoantibodies.
Related Posts
Akoya PhenoImager-HT 2.0 Brochure
Human Neurobiology PhenoCode Discovery Panel
Building Custom High-Plex Biomarker Panels
Scale Your Spatial Discoveries with Molecular Barcoding
Spatial Analysis
PhenoCode Molecular Barcoding Kit
Introducing the Metabolism Spike-in Module for IO60
Neurology
NfL Fact Sheet
Neurofilament light (NfL) has emerged in recent years as a blood-based biomarker with the potential to aid in the improvement of early diagnosis and patient care of neuro-axonal injury and…
Neurology
Cytokine 4-Plex Advantage PLUS Product Flyer
Ultra-Sensitive, Fully Automated Simoa® Cytokine 4-Plex Advantage PLUS Assays Three panels, 11 essential cytokine biomarkers, femtogram sensitivity With Simoa® ultra-sensitive protein quantification, the cutting-edge Advantage PLUS assay platform, and full…